Our Company

Over the last 20 years, our research has focused on investigating the underlying mechanisms by which cancers can survive and evade the effects of chemotherapy. This research led to the identification of novel drug targets that now form the basis for innovative strategies to improve the effectiveness of the most widely prescribed cornerstone chemotherapies. CV6 Therapeutics was founded in 2013 to accelerate the development of these novel targeted small molecule therapeutics. CV6 Therapeutics’ first oncology drug, CV6-168, has completed pre-clinical development and is poised to enter clinical trials.